Rachel Sparks

Rachel Sparks

Auto-generated profile, based on publicly available information

Rachel Sparks

Multiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Cell
Verified
Journal Article
Closed access
CLCan Liu
Can Liu
AMAndrew J. Martins
Andrew J. Martins
WLWilliam W. Lau
William W. Lau
NRNicholas Rachmaninoff
Nicholas Rachmaninoff
JCJinguo Chen
Jinguo Chen
JTJohn S. Tsang
John S. Tsang

4 January 2023 in Nature
Verified
Journal Article
Open access
PDF file
RSRachel Sparks
Rachel Sparks
WLWilliam W. Lau
William W. Lau
CLCan Liu
Can Liu
KHKyu Lee Han
Kyu Lee Han
KVKiera L. Vrindten
Kiera L. Vrindten
DSDeitra Shipman
Deitra Shipman
Acute viral infections can have durable functional impacts on the immune system long after recovery, but how they affect homeostatic immune states and responses to future perturbations remain poorly understood1,2,3,4. Here we use systems immunology approaches, including longitudinal multimodal single-cell analysis (surface proteins, transcriptome and V(D)J sequences) to comparatively assess baseline immune statuses and responses to influenza vaccination in 33 healthy individuals after recovery from mild, non-hospitalized COVID-19 (mean, 151 days after diagnosis) and 40 age- and sex-matched control individuals who had never had COVID-19. At the baseline and independent of time after COVID-19, recoverees had elevated T cell activation signatures and lower expression of innate immune genes including Toll-like receptors in monocytes. Male individuals who had recovered from COVID-19 had coordinately higher innate, influenza-specific plasmablast, and antibody responses after vaccination compared with healthy male individuals and female individuals who had recovered from COVID-19, in part because male recoverees had monocytes with higher IL-15 responses early after vaccination coupled with elevated prevaccination frequencies of ‘virtual memory’-like CD8+ T cells poised to produce more IFNγ after IL-15 stimulation. Moreover, the expression of the repressed innate immune genes in monocytes increased by day 1 to day 28 after vaccination in recoverees, therefore moving towards the prevaccination baseline of the healthy control individuals. By contrast, these genes decreased on day 1 and returned to the baseline by day 28 in the control individuals. Our study reveals sex-dimorphic effects of previous mild COVID-19 and suggests that viral infections in humans can establish new immunological set-points that affect future immune responses in an antigen-agnostic manner.

16 April 2022 in medRxiv
Verified
Preprint
Open access
PDF file
NVNicole Vasilevsky
Nicole Vasilevsky
NMNicolas A Matentzoglu
Nicolas A Matentzoglu
STSabrina Toro
Sabrina Toro
JFJoseph E Flack
Joseph E Flack
HHHarshad Hegde
Harshad Hegde
JMJulie A McMurry
Julie A McMurry
There are thousands of distinct disease entities and concepts, each of which are known by different and sometimes contradictory names. The lack of a unified system for managing these entities poses a major challenge for both machines and humans that need to harmonize information to better predict causes and treatments for disease. The Mondo Disease Ontology is an open, community-driven ontology that integrates key medical and biomedical terminologies, supporting disease data integration to improve diagnosis, treatment, and translational research. Mondo records the sources of all data and is continually updated, making it suitable for research and clinical applications that require up-to-date disease knowledge.

3 July 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RSRachel Sparks
Rachel Sparks
NRNicholas Rachmaninoff
Nicholas Rachmaninoff
WLWilliam W. Lau
William W. Lau
DHDylan C. Hirsch
Dylan C. Hirsch
NBNeha Bansal
Neha Bansal
JTJohn S. Tsang
John S. Tsang

13 October 2023 in Science Advances
Verified
Journal Article
Open access
MZMackenzie Zendt
Mackenzie Zendt
FCFausto A. Bustos Carrillo
Fausto A. Bustos Carrillo
SKSophie Kelly
Sophie Kelly
TSTaylor Saturday
Taylor Saturday
MDMaureen DeGrange
Maureen DeGrange
EREmily E. Ricotta
Emily E. Ricotta
Research on coronavirus disease 2019 vaccination in immune-deficient/disordered people (IDP) has focused on cancer and organ transplantation populations. In a prospective cohort of 195 IDP and 35 healthy volunteers (HV), antispike immunoglobulin G (IgG) was detected in 88% of IDP after dose 2, increasing to 93% by 6 months after dose 3. Despite high seroconversion, median IgG levels for IDP never surpassed one-third that of HV. IgG binding to Omicron BA.1 was lowest among variants. Angiotensin-converting enzyme 2 pseudo-neutralization only modestly correlated with antispike IgG concentration. IgG levels were not significantly altered by receipt of different messenger RNA–based vaccines, immunomodulating treatments, and prior severe acute respiratory syndrome coronavirus 2 infections. While our data show that three doses of coronavirus disease 2019 vaccinations induce antispike IgG in most IDP, additional doses are needed to increase protection. Because of the notably reduced IgG response to Omicron BA.1, the efficacy of additional vaccinations, including bivalent vaccines, should be studied in this population.

1 September 2022 in medRxiv
Verified
Preprint
Open access
PDF file
RSRachel Sparks
Rachel Sparks
WLWilliam W. Lau
William W. Lau
CLCan Liu
Can Liu
KHKyu Lee Han
Kyu Lee Han
KVKiera L. Vrindten
Kiera L. Vrindten
JTJohn S. Tsang
John S. Tsang
Viral infections can have profound and durable functional impacts on the immune system. There is an urgent need to characterize the long-term immune effects of SARS-CoV-2 infection given the persistence of symptoms in some individuals and the continued threat of novel variants. Here we use systems immunology, including longitudinal multimodal single cell analysis (surface proteins, transcriptome, and V(D)J sequences) from 33 previously healthy individuals after recovery from mild, non-hospitalized COVID-19 and 40 age- and sex-matched healthy controls with no history of COVID-19 to comparatively assess the post-infection immune status (mean: 151 days after diagnosis) and subsequent innate and adaptive responses to seasonal influenza vaccination. Identification of both sex-specific and -independent temporally stable changes, including signatures of T-cell activation and repression of innate defense/immune receptor genes (e.g., Toll-like receptors) in monocytes, suggest that mild COVID-19 can establish new post-recovery immunological set-points. COVID-19-recovered males had higher innate, influenza-specific plasmablast, and antibody responses after vaccination compared to healthy males and COVID-19-recovered females, partly attributable to elevated pre-vaccination frequencies of a GPR56 expressing CD8+ T-cell subset in male recoverees that are “poised” to produce higher levels of IFNγ upon inflammatory stimulation. Intriguingly, by day 1 post-vaccination in COVID-19-recovered subjects, the expression of the repressed genes in monocytes increased and moved towards the pre-vaccination baseline of healthy controls, suggesting that the acute inflammation induced by vaccination could partly reset the immune states established by mild COVID-19. Our study reveals sex-dimorphic immune imprints and in vivo functional impacts of mild COVID-19 in humans, suggesting that prior COVID-19, and possibly respiratory viral infections in general, could change future responses to vaccination and in turn, vaccines could help reset the immune system after COVID-19, both in an antigen-agnostic manner.